新型抗栓药物替格瑞洛在急性冠脉综合征治疗中的应用研究进展
《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]
- 期数:
- 2017年第5期
- 页码:
- 605-609,613
- 栏目:
- 综述
- 出版日期:
- 2017-03-25
文章信息/Info
- Title:
- Research progress in application of new antithrombtic drug Ticagrelor in treatment of acute coronary syndrome
- Author(s):
- ZHANG Liang1; YUAN Ming1; CAO Feng2
- (1.Department of Cardiology, Xijing Hospital, Fourth Military Medical University, Xi’an 710032, Shaanxi, China；
2.Department of Cardiology, PLA General Hospital, Beijing 100853, China)
- Keywords:
- ticagrelor; acute coronary syndrome; research progress
- 分类号:
- R543.3
- DOI:
- -
- 文献标识码:
- A
- 摘要:
- 急性冠脉综合征（ACS）是威胁人类健康的重大疾病。双联抗血小板治疗是ACS患者治疗的基石。氯吡格雷作为经典的抗血小板药物，在临床应用的过程中显现出许多不足，替格瑞洛由于其特殊的药代动力学和药效学特征，克服了氯吡格雷的缺陷，国内外许多大型临床研究已经证实在治疗ACS患者中的优越性，极大地降低了ACS患者的主要不良心血管事件。新的研究不断问世，为替格瑞洛提供了大量的循证医学证据。本文将对替格瑞洛的药理学特征、目前的临床研究及相应的指南作一综述。
- Abstract:
- Acute coronary syndrome (ACS) is a severe disease which threatens human health. Dual antiplatelet is the cornerstone of the treatment of ACS. Clopidogrel, as a classical antiplatelet drug, has showed several flaws. However,Ticagrelor, a new antithrombtic drug, overcomes those deficiencies thanks to its special pharmacokinetic and pharmacodynamics characteristics. Many large clinical studies have confirmed the advantages of Ticagrelor in treatment of ACS patients with acute coronary syndrome as it greatly reduces the major cardiac events in ACS patients. New studies have provided a large number of evidence-based medical evidence and this paper is to review the pharmacological characteristics, current clinical studies and corresponding guidelines of Ticagrelor.
参考文献/References
[1]World Health Organization.Top ten causes of death.Geneva:World Health Organization;2011[OL].http://www.who.int/mediacentre/factsheets/fs310/en/
[2]Sangu P,Ranasinghe I,Aliprandib,et al.Trends and predictors of rehospitalisation following an acute coronary syndrome:report from the Australian and New Zealand population of the Global Registry of Acute Coronary Events(GRACE)[J].Heart,2012,98(23):1728-1731.
[3]陈伟伟,高润霖,刘力生,等.中国心血管病报告2013概要[J].中国循环杂志,2014,29(7):487-491.
[4]Brar SS,ten Berg J,Marcucci R,et al.Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention.A collaborative meta-analysis of individual participant data[J].J Am Coll Cardiol,2011,58(19):1945-1954.
[5]Singh M,Thapa B,Arora R.Clopidogerl pharmacogenetics and its clinical implications[J].Am J Ther,2010,17(3):e66-e73.
[6]WijeyeratneYD,Joshi R,Heptinstall S.Ticagrelor:a P2Y12 antagonist for use in acute coronary syndromes[J].Expert Rev CIin Pharmacol,2012,5(3):257-269.
[7]Butler K,Teng R.Pharmacokinetics,pharmacodynamics, and safety of ticagrelor in volunteers with mild hepatic impairment[J].J Clin Pharmacol,2011,51(7):978-987.
[8]Ramaraj R,Movahed MR,Hashemzadeh M.Novel antiplatelet agent ticagrelor in the management of acute coronary syndrome[J].J lnterv Cardiel,2011,24(3):199-207.
[9]Huber K,Hamad B,Kirkparick P.Fresh from the pipeline ticagrelor[J].Nat Rev Drug Discov,2011,10(4):255-256.
[10]Gurbel PA,Bliden KP,Butler K,et al.Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease:the ONSET/OFFSET study[J].Circulation,2009,120(25):2577-2585.
[11]Chen YD,Dong W,Wan Z,et al.Ticagrelor versus clopidogrel in Chinese patients with acute coronary syndrome:A pharmacodynamic analysis Int[J].Int J Cardiol,2015,201:545-546.
[12]Cuisset T,Cayla G,Silvain J.Clopidogrel resistance:What’s new?[J].Arch Cardiovase Dis,2010,103(67):349-353.
[13]Gurbel PA,Bliden KP,Butler K,et al.Response to Ticagrelor in Clopidogrel Nonresponders and Responders and Effect of Switching Therapies The RESPOND Study[J].Circulation,2010,121(10):1188-1199.
[14]Wallentin L,Becker RC,Budaj A,et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes[J].N Engl J Med,2009,361(11):1045-1057.
[15]Cannon CP,Harrington RA,James S,et al.Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO):a randomised double-blind study[J].Lancet,2010,375(9711):283-293.
[16]Montalescot G,Lassen JF,Hamm CW,et al.Ambulance or in-catheterization laboratory administration of ticagrelor for primary percutaneous coronary intervention for ST-segment elevation myocardial infarction:rationale and design of the randomized, double-blind Administration of Ticagrelor in the cath Lab or in the Ambulance for New ST elevation myocardial Infarction to open the Coronary artery(ATLANTIC)study[J].Am Heart J,2013,165(4):515-522.
[17]James SK,Roe MT,Cannon CP,et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomized PLATelet inhibition and patient Outcomes (PLATO)trial[J].BMJ,2011,342:d3527.
[18]Held C,Asenblad N,Bassand JP,et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery:results from the PLATO(Platelet Inhibition and Patient Outcomes)trial[J].J Am Coll Cardiol,2011,57(6):672-684.
[19]James S,Angiolillo DJ,Cornel JH,et al.Ticagrelor vs.clopidogrel in patients with acute coronary syndromes and diabetes:a substudy from the Platelet inhibition and patient Outcomes(PLATO)trial[J].Eur Heart J,2010,31(24):3006-3016.
[20]James S,Budaj A,Aylward P,et al.Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function:results from the Platelet Inhibition and Patient Outcomes(PLATO)trial[J].Circulation,2010,122(11):1056-1067.
[21]Uegami S,Ikawa K,Ohge H,et al.Phannacokinelics and pharmacodvnamic target attainment of intravenous pazunoxacin in the bile of patients under90ing biliary pancreatic surgery[J].J Chemolher,2014,26(5):287-292.
[22]Burki NK,Dale WJ,Lee LY.Intravenous adenosine and dyspnea in humans[J].J Appl Physiol,2005,98(1):180-185.
[23]Ohman J,Kudira R,Albinsson S,et al.Ticagrelor induces adenosine triphosphate release from human red blood cells[J].Biochem Biophys Res Commun,2012,418(4):754-758.
[24]Ohman J,Kudira R,Albinsson S,et al.Ticagrelor induces adenosine triphosphate release from human red blood cells[J].Biochem Biophys Res Commun,2012,418(4):754-758.
[25]Wittfeldt A,Emanuelsson H,Brandrup-Wognsen G,et al.Ticagrelor enhances adenosine induced coronary vasodilatory responses irt humans[J].J Am Coll Cardiol,2013,61(7):723-727.
[26]Alexopoulos D,Moulias A,Koutsogiannis N,et al.Differential efect of tieagrelor versus prasugrel on coronary blood flow velocity in patients with non-STelevation acute coronary syndrome undergoing percutaneous coronary intervention:an exploratory study[J].Circ Cardiovasc Interv,2013,6(3):277-283.
[27]Nylander S,Femiae A,Scavone M,et al.Ticagrelor inhibits human platelet aggregation via adenosine in addition to P2Y12 antagonism[J].J Thromb Haemost,2013,11(10):1867-1876.
[28]BirnbaumY,Ling S,Nanhwanm K,et al.Ticagrelor but not clopidogrel protects the heart and limits myocardial infarct size[J].J Am Coil Cardiol,2014,63(12):A22.
[29]Bonaca MP,Bhatt DL,Cohen M,et al.Long-term use of ticagrelor in patients with prior myocardial infarction[J].N Engl J Med,2015,372(19):1791-1800.
[30]Windecker S,Kolh P,Alfonso F,et al.2014 ESC/EACTS Guidelines on myocardial revascularization:The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery(EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions(EAPCI)[J].Eur Heart J,2014,35(37):2541-2619.
[31]Amsterdam EA,Wenger NK,Brindis RG,et al.2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines[J].Circulation,2014,130(25):e344-e426.
[32]Roffi M,Patrono C,Collet JP,et al.2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC)[J].Eur Heart J,2016,37(3):267-315.
备注/Memo
- 备注/Memo:
- 收稿日期：2016-05-23.
基金项目：陕西省科技攻关计划课题资助(S2016 YFSF0666)
通讯作者：袁铭，副教授，主要从事冠心病的基础及复杂冠脉介入治疗 Email:yuanming@fmmu.edu.cn 共同
通讯作者：曹丰，教授，主要从事冠心病的诊断和治疗及心血管分子影像学研究 Email:fengcao8828@163.com
作者简介：张亮，硕士生 Email:zhangliang199096@163.com
常用功能
统计/Statistics
- 摘要浏览/Viewed863
- 评论/Comments
